Clinical Trials List
2022-05-01 - 2025-05-09
Phase III
Recruiting7
ICD-10C56.1
Malignant neoplasm of right ovary
ICD-10C56.2
Malignant neoplasm of left ovary
ICD-10C56.9
Malignant neoplasm of unspecified ovary
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9183.0
Malignant neoplasm of ovary
-
Trial Applicant
MEDPACE TAIWAN LIMITED
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 吳珮瑩 無
- 林語涵 Division of Obstetrics & Gynecology
- 鄭雅敏 Division of Obstetrics & Gynecology
- 黃蘭茵 無
- Meng-Ru Shen Division of Obstetrics & Gynecology
- 江佳蓉 Division of Obstetrics & Gynecology
- Cheng-Yang Chou Division of Obstetrics & Gynecology
- 林語涵 無
- 黃蘭茵 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Huann-Cheng Horng Division of Obstetrics & Gynecology
- Yi-Jen Chen Division of Obstetrics & Gynecology
- 沈書慧 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ting-Chang Chang 無
- HSIU-JUNG TUNG 無
- Min-Yu Chen 無
- 張宸邠 無
- 周宏學 無
- 黃寬仁 無
- Huei-Jean Huang 無
- 黃彥綾 無
- Cheng-Tao Lin 無
- Yun-Hsin Tang 無
- Gigin Lin 無
- 陳威君 無
- Angel Chao 無
- 張淑涵 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- YING-CHENG CHIANG Division of Obstetrics & Gynecology
- 郭冠廷 Division of Obstetrics & Gynecology
- 施怡倫 Division of Obstetrics & Gynecology
- 童寶玲 Division of Obstetrics & Gynecology
- 戴依柔 Division of Obstetrics & Gynecology
- Wen-Fang Cheng 無
- 陳宇立 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yin-Yi Chang 無
- Wei-Chun Chang 無
- Wei-Ching Lin 無
- Wu-Chou Lin 無
- 宋鈺雯 無
- 黃千竹 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
35 participants
-
Global
376 participants